BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

767 related articles for article (PubMed ID: 12469184)

  • 1. Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines.
    Concin N; Stimpfl M; Zeillinger C; Wolff U; Hefler L; Sedlak J; Leodolter S; Zeillinger R
    Int J Oncol; 2003 Jan; 22(1):51-7. PubMed ID: 12469184
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irradiation induces G2/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expression.
    Strasser-Wozak EM; Hartmann BL; Geley S; Sgonc R; Böck G; AJ Santos ; Hattmannstorfer R; Wolf H; Pavelka M; Kofler R
    Cell Death Differ; 1998 Aug; 5(8):687-93. PubMed ID: 10200524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations.
    Delia D; Goi K; Mizutani S; Yamada T; Aiello A; Fontanella E; Lamorte G; Iwata S; Ishioka C; Krajewski S; Reed JC; Pierotti MA
    Oncogene; 1997 May; 14(18):2137-47. PubMed ID: 9174049
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G2/M checkpoint is p53-dependent and independent after irradiation in five human sarcoma cell lines.
    Bache M; Dunst J; Würl P; Fröde D; Meye A; Schmidt H; Rath FW; Taubert H
    Anticancer Res; 1999; 19(3A):1827-32. PubMed ID: 10470122
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-dependent changes in factors involved in the apoptotic process in human ovarian cancer cells as a response to cisplatin.
    Kolfschoten GM; Hulscher TM; Schrier SM; van Houten VM; Pinedo HM; Boven E
    Gynecol Oncol; 2002 Mar; 84(3):404-12. PubMed ID: 11855878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Explaining differences in sensitivity to killing by ionizing radiation between human lymphoid cell lines.
    Aldridge DR; Radford IR
    Cancer Res; 1998 Jul; 58(13):2817-24. PubMed ID: 9661896
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2/Bax protein ratio predicts 5-fluorouracil sensitivity independently of p53 status.
    Mirjolet JF; Barberi-Heyob M; Didelot C; Peyrat JP; Abecassis J; Millon R; Merlin JL
    Br J Cancer; 2000 Nov; 83(10):1380-6. PubMed ID: 11044365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cell-cycle mediators in ovarian cancer cells after transfection with p16(INK4a), p21(WAF1/Cip-1), and p53.
    Ramirez PT; Gershenson DM; Tortolero-Luna G; Ramondetta LM; Fightmaster D; Wharton JT; Wolf JK
    Gynecol Oncol; 2001 Dec; 83(3):543-8. PubMed ID: 11733969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity.
    Giannakakou P; Robey R; Fojo T; Blagosklonny MV
    Oncogene; 2001 Jun; 20(29):3806-13. PubMed ID: 11439344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of wild type p53 in the G2 phase: regulation of the gamma-irradiation-induced delay and DNA repair.
    Schwartz D; Almog N; Peled A; Goldfinger N; Rotter V
    Oncogene; 1997 Nov; 15(21):2597-607. PubMed ID: 9399647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development and validation of sensitive assays to quantitate gene expression after p53 gene therapy and paclitaxel chemotherapy using in vivo dosing in tumor xenograft models.
    Wen SF; Xie L; McDonald M; DiGiacomo R; Chang A; Gurnani M; Shi B; Liu S; Indelicato SR; Hutchins B; Nielsen LL
    Cancer Gene Ther; 2000 Nov; 7(11):1469-80. PubMed ID: 11129289
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells.
    Strobel T; Swanson L; Korsmeyer S; Cannistra SA
    Oncogene; 1997 Jun; 14(23):2753-8. PubMed ID: 9190890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis and cell cycle-specific change in expression of p53 in normal lymphocytes and MOLT-4 leukemic cells by nitrogen mustard.
    Bhatia U; Danishefsky K; Traganos F; Darzynkiewicz Z
    Clin Cancer Res; 1995 Aug; 1(8):873-80. PubMed ID: 9816057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A transcriptional activation function of p53 is dispensable for and inhibitory of its apoptotic function.
    Kokontis JM; Wagner AJ; O'Leary M; Liao S; Hay N
    Oncogene; 2001 Feb; 20(6):659-68. PubMed ID: 11313999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiosensitivity, apoptosis and repair of DNA double-strand breaks in radiation-sensitive Chinese hamster ovary cell mutants treated at different dose rates.
    Hu Q; Hill RP
    Radiat Res; 1996 Dec; 146(6):636-45. PubMed ID: 8955713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. p53 status does not affect sensitivity of human ovarian cancer cell lines to paclitaxel.
    Debernardis D; Siré EG; De Feudis P; Vikhanskaya F; Valenti M; Russo P; Parodi S; D'Incalci M; Broggini M
    Cancer Res; 1997 Mar; 57(5):870-4. PubMed ID: 9041188
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p53 apoptotic response to DNA damage dependent on bcl2 but not bax in head and neck squamous cell carcinoma lines.
    Crowe DL; Sinha UK
    Head Neck; 2006 Jan; 28(1):15-23. PubMed ID: 16302195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. p53 involvement in control of G2 exit of the cell cycle: role in DNA damage-induced apoptosis.
    Guillouf C; Rosselli F; Krishnaraju K; Moustacchi E; Hoffman B; Liebermann DA
    Oncogene; 1995 Jun; 10(11):2263-70. PubMed ID: 7784074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation.
    Ning S; Knox SJ
    Radiat Res; 1999 Jun; 151(6):659-69. PubMed ID: 10360785
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.